Financials in USD. Standardized financial statements.
A compact view of how China Pharma Holdings, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $4.14M | $4.53M | $7.01M | $8.10M | $9.64M | $10.87M | $10.92M | $12.33M | $13.21M | $15.57M |
| Revenue Growth? | -8.5% | -35.4% | -13.5% | -15.9% | -11.3% | -0.5% | -11.4% | -6.7% | -15.1% | 0.0% |
| Cost of Revenue? | $4.28M | $6.51M | $7.29M | $8.60M | $9.29M | $8.91M | $9.44M | $10.36M | $10.74M | $12.35M |
| Gross Profit? | -$131,950 | -$1.99M | -$281,085 | -$493,916 | $349,270 | $1.95M | $1.48M | $1.97M | $2.47M | $3.22M |
| Gross Margin? | -3.2% | -43.8% | -4.0% | -6.1% | +3.6% | +18.0% | +13.6% | +16.0% | +18.7% | +20.7% |
| Operating Expenses? | $2.96M | $2.60M | $2.47M | $3.06M | $3.21M | $4.53M | $4.87M | -$12.42M | -$21.15M | -$11.37M |
| Operating Income? | -$3.09M | -$4.59M | -$2.75M | -$3.55M | -$2.86M | -$2.58M | -$3.39M | -$3.97M | -$4.50M | -$4.19M |
| EBITDA? | -$1.51M | -$1.96M | $8,436 | -$837,689 | $230,345 | $106,852 | -$17.45M | -$7.15M | -$15.32M | -$4.95M |
| Income Before Tax | -$3.19M | -$4.74M | -$3.08M | -$3.97M | -$3.40M | -$2.87M | -$20.70M | -$10.86M | -$19.15M | -$8.87M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$109,989 | $122,631 | $308,175 |
| Net Income? | -$3.19M | -$4.74M | -$3.08M | -$3.97M | -$3.40M | -$2.87M | -$20.70M | -$10.75M | -$19.28M | -$9.18M |
| EPS? | $-0.74 | $-0.27 | $-0.29 | $-1.94 | $-0.85 | $-0.72 | $-4.82 | $-2.47 | $-4.42 | $-2.11 |
| Diluted EPS? | $-0.74 | $-0.27 | $-0.29 | $-1.94 | $-0.85 | $-0.72 | $-4.82 | $-2.47 | $-4.42 | $-2.11 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality